Viemed Healthcare, Inc. (VMD) AI Stock Analysis

Viemed Healthcare, Inc. delivers in-home durable medical equipment and post-acute respiratory healthcare services across the United States. The company specializes in comprehensive respiratory disease management solutions, particularly for patients with chronic obstructive pulmonary disease. Its offerings include the sale and leasing of non-invasive and invasive ventilators, positive airway pressure machines, automatic CPAP, bi-level devices, percussion vests, and oxygen concentrator units. Viemed Healthcare also provides specialized neuromuscular care, oxygen therapy services, sleep apnea management solutions, and in-home sleep apnea testing services, ensuring access to essential respiratory care and medical equipment.

Viemed Healthcare grew annual revenue from $117.1M in FY2021 to $270.3M in FY2025, representing a 5-year revenue CAGR of 15.5%. Annual revenue growth reached 31.8% in FY2023, 22.5% in FY2024, and 20.5% in FY2025. Over the same period, gross margin contracted from 62.7% in FY2021 to 57.5% in FY2025, and operating margin declined from 9.9% in FY2021 to 7.7% in FY2025. Annual net income increased from $9.1M in FY2021 to $14.9M in FY2025, resulting in an EPS of $0.37. Over the trailing twelve months, revenue reached $301.6M with a profit margin of 4.8%. In the latest quarter ended June 30, 2026, quarterly revenue rose 23.9% year-over-year, while quarterly earnings declined 12.4%.

As of June 30, 2026, Viemed Healthcare held $10.7M in cash and short-term investments against total debt of $11.6M, leaving net debt at $920,000. Total assets stood at $204.2M and shareholders' equity was $144.0M, resulting in a debt-to-equity ratio of 0.08 and a current ratio of 1.13. For FY2025, operating cash flow reached $51.9M and free cash flow was $11.9M after capital expenditures of $40.0M. The company also deployed $13.2M toward share buybacks in FY2025.

At a last close of $9.48, Viemed Healthcare has a market cap of $361.1M and an enterprise value of $336.5M. The stock trades at a trailing P/E of 26.3x and a forward P/E of 18.3x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its EV/EBITDA of 5.9x trades below the peer median of 12.0x, and its price-to-sales ratio of 1.2x is below the peer median of 4.1x. Over the past year, VMD gained 38.4% compared to a 16.8% return for the S&P 500, while its 5-year return of 64.3% trailed the index's 83.0%.

Analyst coverage consists of 1 Buy, 1 Hold, and 0 Sell ratings. The mean price target is $12.50, which is 31.9% above the last close price of $9.48. For the fiscal year ending December 31, 2026, estimates project revenue of $317.9M and EPS of $0.41, representing 11.7% EPS growth. For the next fiscal year, 3 analysts project revenue of $353.6M and EPS of $0.54. Viemed Healthcare beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Viemed Healthcare, Inc. (VMD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VMD income statement, VMD balance sheet, VMD key metrics, VMD analyst forecast, VMD chart. See the VMD stock overview for the latest quote and news.